Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus (CMV) infections, with widespread application particularly in patients with acquired immunodeficiency syndrome (AIDS) and organ transplant recipients. This article provides a detailed introduction from three aspects: the latest price of valganciclovir, medication preparation, and contraindications, to help patients and healthcare practitioners gain a better understanding of this drugNCBI.
Updated Price List for Valganciclovir
The price of valganciclovir may vary due to factors such as exchange rates; the following prices are for reference only:
Lao Da Xiong Version of Valganciclovir
The specification is 450 mg * 60 tablets per box, and the price is approximately 148 US dollars per box. When choosing a drug version, patients should select the appropriate one based on their financial conditions and the advice of their doctors.
Medication Preparation for Valganciclovir
Medication preparation for valganciclovir involves multiple aspects, including dosage form selection, administration method, and storage conditions.
Dosage Form Selection
Adult patients should use tablets, while pediatric patients may choose tablets or oral solution. Tablets should not be broken or crushed and must be swallowed whole.
Administration Method
Valganciclovir should be taken with food to improve bioavailability. The oral solution needs to be prepared by a pharmacist, stored under refrigeration after preparation, and used within 49 days.
Storage Conditions
Tablets should be stored at room temperature (20°C to 25°C) and must not be frozen.
Proper medication preparation can help patients maximize the therapeutic efficacy of the drug and reduce unnecessary adverse reactions.
Contraindications of Valganciclovir
Valganciclovir is not suitable for all populations; special attention should be paid to the following situationsFDA Access Data.
Hypersensitivity Reactions
Patients with a known hypersensitivity to valganciclovir or ganciclovir are contraindicated from using valganciclovir. Hypersensitivity reactions may manifest as rash, dyspnea, etc., and the drug should be discontinued immediately and medical attention sought.
Renal Impairment
For patients with renal impairment receiving valganciclovir, dose reduction is recommended. Patients with severe renal insufficiency or those undergoing hemodialysis should avoid using this drug, and renal function should be monitored regularly during treatment.
Pregnant and Lactating Women
Valganciclovir may cause harm to the fetus and is contraindicated in pregnant women. Lactating women should also avoid using it to prevent the drug from affecting infants through breast milk.
Understanding contraindications helps patients avoid medication risks, and patients must use this drug under the guidance of a doctor.
